BTIG reiterates Buy rating on Acumen Pharmaceuticals; $8 target
BTIG reiterated a Buy rating on Acumen Pharmaceuticals and set a $8.00 price target, implying 176.8% upside from the Sep 15 close of $2.89.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.